The proposed legislation, General Assembly Raised Bill No. 191, aims to establish a psychedelic-assisted therapy pilot program in Connecticut, effective July 1, 2026. The bill defines key terms such as "MDMA" and "psilocybin," and introduces the concept of a "qualified patient," which includes individuals aged eighteen or older who meet specific clinical eligibility criteria set by the institutional review board of the administering medical school. Eligible patients are defined as residents of the state who are veterans, retired first responders, or direct care healthcare workers.

The bill also modifies the existing framework for the pilot program by removing a previous deadline for its establishment and allowing the Department of Mental Health and Addiction Services to operate the program until MDMA and psilocybin receive medical approval from the Drug Enforcement Administration. This change reflects a commitment to expanding access to psychedelic-assisted therapy as part of a research initiative approved by the federal Food and Drug Administration.

Statutes affected:
Raised Bill: